Back to Search Start Over

TRAK2, a novel regulator of ABCA1 expression, cholesterol efflux and HDL biogenesis.

Authors :
Lake NJ
Taylor RL
Trahair H
Harikrishnan KN
Curran JE
Almeida M
Kulkarni H
Mukhamedova N
Hoang A
Low H
Murphy AJ
Johnson MP
Dyer TD
Mahaney MC
Göring HHH
Moses EK
Sviridov D
Blangero J
Jowett JBM
Bozaoglu K
Source :
European heart journal [Eur Heart J] 2017 Dec 21; Vol. 38 (48), pp. 3579-3587.
Publication Year :
2017

Abstract

Aims: The recent failures of HDL-raising therapies have underscored our incomplete understanding of HDL biology. Therefore there is an urgent need to comprehensively investigate HDL metabolism to enable the development of effective HDL-centric therapies. To identify novel regulators of HDL metabolism, we performed a joint analysis of human genetic, transcriptomic, and plasma HDL-cholesterol (HDL-C) concentration data and identified a novel association between trafficking protein, kinesin binding 2 (TRAK2) and HDL-C concentration. Here we characterize the molecular basis of the novel association between TRAK2 and HDL-cholesterol concentration.<br />Methods and Results: Analysis of lymphocyte transcriptomic data together with plasma HDL from the San Antonio Family Heart Study (n = 1240) revealed a significant negative correlation between TRAK2 mRNA levels and HDL-C concentration, HDL particle diameter and HDL subspecies heterogeneity. TRAK2 siRNA-mediated knockdown significantly increased cholesterol efflux to apolipoprotein A-I and isolated HDL from human macrophage (THP-1) and liver (HepG2) cells by increasing the mRNA and protein expression of the cholesterol transporter ATP-binding cassette, sub-family A member 1 (ABCA1). The effect of TRAK2 knockdown on cholesterol efflux was abolished in the absence of ABCA1, indicating that TRAK2 functions in an ABCA1-dependent efflux pathway. TRAK2 knockdown significantly increased liver X receptor (LXR) binding at the ABCA1 promoter, establishing TRAK2 as a regulator of LXR-mediated transcription of ABCA1.<br />Conclusion: We show, for the first time, that TRAK2 is a novel regulator of LXR-mediated ABCA1 expression, cholesterol efflux, and HDL biogenesis. TRAK2 may therefore be an important target in the development of anti-atherosclerotic therapies.<br /> (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017. For permissions, please email: journals.permissions@oup.com.)

Details

Language :
English
ISSN :
1522-9645
Volume :
38
Issue :
48
Database :
MEDLINE
Journal :
European heart journal
Publication Type :
Academic Journal
Accession number :
28655204
Full Text :
https://doi.org/10.1093/eurheartj/ehx315